Approval · Notice of Compliance 15656 · 2014
ACT SIMVASTATIN: Notice of Compliance 15656
Issued May 28, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15656
- Date
- May 28, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Lipid metabolism regulator
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT SIMVASTATIN | 02248103 | Cancelled Post Market |
| ACT SIMVASTATIN | 02248104 | Cancelled Post Market |
| ACT SIMVASTATIN | 02248105 | Cancelled Post Market |
| ACT SIMVASTATIN | 02248106 | Cancelled Post Market |
| ACT SIMVASTATIN | 02248107 | Cancelled Post Market |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB